The spin stops here: inhibition of lipoprotein-associated phospholipase A2-- a promising target but a negative initial trial?
McConnell
Joseph P
JP
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Jaffe
Allan S
AS
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors* / Q000097:blood; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D001547:Benzaldehydes / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D010091:Oximes / Q000494:pharmacology* / Q000627:therapeutic use; D017211:Treatment Failure; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001547:Benzaldehydes; D015415:Biomarkers; D010091:Oximes; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides